Pharmacokinetics of vancomycin in patients with various degrees of renal function.

Antimicrobial Agents and Chemotherapy
G R MatzkeW F Keane

Abstract

The pharmacokinetics of vancomycin were characterized in 56 patients with different degrees of renal function after an intravenous dose of 18.4 +/- 4.7 mg kg-1 (mean +/- standard deviation). Seven subjects had a creatinine clearance (CLCR) of greater than 60 ml min-1 (group I), 13 had a CLCR of 10 to 60 ml min-1 (group II), and 36 had a CLCR of less than 10 ml min-1 (group III). Serial serum samples (range, 3 to 8) were collected during the 168 h after drug administration. The serum concentration-time profile in all patients demonstrated monoexponential decay. The mean half-lives were 9.1, 32.3, and 146.7 h in groups I, II, and III, respectively. A significant decline in serum clearance (CLS) was also noted (62.7 to 28.3 to 4.87 ml min-1 in groups I, II, and III, respectively). The steady-state volume of distribution varied from 0.72 to 0.90 liter kg-1. There was no significant relationship between the steady-state volume of distribution and CLCR. The observed relationship between CLS and CLCR (CLS = 3.66 + 0.689 CLCR; r = 0.8807) can be utilized to devise dosage schedules for patients with any degree of renal impairment. This relationship was utilized to develop a nomogram for initial and maintenance dosing of vancomycin.

References

Jan 1, 1979·Nephron·H E NielsenH E Hansen
Apr 1, 1975·Acta Medica Scandinavica·H E NielsenP E Skov
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Aug 1, 1971·The American Journal of the Medical Sciences·A J Morris, R T Bilinsky
May 12, 1966·The New England Journal of Medicine·D D Lindholm, J S Murray
Mar 1, 1981·Annals of Internal Medicine·R C MoelleringD J Greenblatt
Sep 1, 1982·Antimicrobial Agents and Chemotherapy·J C RotschaferL D Solem

❮ Previous
Next ❯

Citations

Sep 19, 1997·Journal of Biomedical Materials Research·K FujimotoY Nimura
Feb 1, 1994·Journal of Clinical Pharmacology·R L Talbert
Jan 1, 1994·International Urology and Nephrology·J AlwakeelH Abu-aisha
Jul 14, 2012·European Journal of Clinical Pharmacology·Yuko ShimamotoKatsuya Komori
Mar 7, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N MakiY Hakamata
Jun 1, 1994·International Journal of Bio-medical Computing·Y Le NormandJ L Harousseau
Jun 1, 1994·International Journal of Bio-medical Computing·M F KerguerisN Milpied
Nov 1, 1991·Mayo Clinic Proceedings·M P Wilhelm
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kurt A Wargo, Edward H Eiland
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald P Levine
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael J Rybak
May 23, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John F Mohr, Barbara E Murray
Sep 19, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marin H Kollef
Sep 10, 2003·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Rosemeire C ZanellaAntonio Carlos C Pignatari
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Merideth BrownHans P Schlecht
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stefaan J VandecasteeleAn Sabine De Vriese
Mar 21, 2009·The Journal of Antimicrobial Chemotherapy·A H ThomsonA M Lovering
Aug 15, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Josée BouchardUNKNOWN Program to Improve Care in Acute Renal Disease
Feb 5, 2011·Current Opinion in Pediatrics·Katherine TwombleyJyothsna Gattineni
Feb 1, 1995·Journal of Clinical Pharmacy and Therapeutics·S Murphy, R J Pinney
Dec 1, 1993·Australian and New Zealand Journal of Medicine·S B DuffullE J Begg
Feb 7, 2008·Seminars in Dialysis·Katie E Pallotta, Harold J Manley
Feb 23, 2011·Seminars in Dialysis·Stefaan J Vandecasteele, An S De Vriese
Mar 1, 1987·Antimicrobial Agents and Chemotherapy·D P HealyT J Comstock
May 1, 1987·Antimicrobial Agents and Chemotherapy·R L DavisA L Smith
Aug 1, 1987·Antimicrobial Agents and Chemotherapy·C FalcozJ Sassard
Jun 1, 1988·Antimicrobial Agents and Chemotherapy·K A RodvoldL J Riff
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·A K HurstE C Harrison
Jul 1, 1990·Antimicrobial Agents and Chemotherapy·T G CantúD M Kornhauser
Mar 1, 1993·Antimicrobial Agents and Chemotherapy·K Vance-BryanJ C Rotschafer
May 1, 1993·Antimicrobial Agents and Chemotherapy·H SunA R Krusell
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Dolores Santos BuelgaMaría José García
Dec 2, 2008·Critical Care : the Official Journal of the Critical Care Forum·A Mary VilayBruce A Mueller
Apr 26, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Takeshi KotakeHideki Morishita
Jun 8, 2000·Clinical Pharmacokinetics·D T Bearden, K A Rodvold
May 14, 2004·Clinical Pharmacokinetics·Matthijs de HoogJohn N van den Anker
Jun 5, 2012·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Nadezda PetejovaIvana Kacirova
Dec 19, 2014·Journal of Intensive Care·Sham SunderPranit Ram
Oct 29, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Thomas D NolinGary R Matzke

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.